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Force production and maintenance in smooth muscle is largely controlled by myosin regulatory light chain (RLC) phosphorylation which relies on a balance between Ca 2+ /calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP) activities.
MYPT1 is the regulatory subunit of MLCP that biochemically inhibits MLCP activity via T694 or T852 phosphorylation in vitro.
Here we separately investigated the contribution of these two phosphorylation sites in bladder smooth muscles by establishing two single point mutation mouse lines, T694A and T852A, and found that phosphorylation of MYPT1 T694, but not T852, mediates force maintenance via inhibition of MLCP activity and enhancement of RLC phosphorylation in vivo.
Our findings reveal the role of MYPT1 T694/T852 phosphorylation in vivo in regulation of smooth muscle contraction.
Abstract Force production and maintenance in smooth muscle is largely controlled by different signaling modules that fine-tune myosin regulatory light chain (RLC) phosphorylation which relies on a balance between Ca 2+ /calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP) activities. To investigate the regulation of MLCP activity in vivo, we analyzed the role of two phosphorylation sites on
MYPT1 (regulatory subunit of MLCP) that biochemically inhibit MLCP activity in vitro.
MYPT1 is constitutively phosphorylated at T694 by unidentified kinases in vivo, whereas T852 site is phosphorylated by ROCK. We established two mouse lines with alanine substitution of T694 or T852. Isolated bladder smooth muscle from T852A mice displayed no significant changes in RLC phosphorylation or force responses, but force was inhibited with a ROCK inhibitor. In contrast, smooth muscles containing T694A mutation showed a significant reduction of force along with reduced RLC phosphorylation. The contractile
Introduction
The walls of hollow organs such as the gastrointestinal tract, circular blood vessels, urinary bladder, airways, and uterus are composed of smooth muscle cells which serve vital homeostatic functions. An initial development of force enables organs to implement quick contractile responses, but they also may maintain force for an extended period of time related to specific physiological functions, e.g. vascular blood vessels for maintaining blood pressure, various sphincters for prolonged closure of an orifice, and emptying of the urinary bladder.
Abnormal contractile performance of smooth muscles contributes to different diseases, such as urinary incontinence, incomplete bladder emptying or retention of urine, hypertension, hypotension, asthma, gut dysmotility, and various reproductive disorders (Uehata et al., 1997; Fernandes et al., 2007; Ohama et al., 2007; He et al., 2008; Fonseca et al., 2009; Meng et al., 2010; Satoh et al., 2011; Zhou et al., 2011; Zderic & Chacko, 2012; Fukumoto & Shimokawa, 2013; He et al., 2013; Hypolite et al., 2013; Stav et al., 2013; Vesterinen et al., 2013) . Thus, force maintenance is a basic physiological property of smooth muscle that is important for diverse functions of different hollow organs.
Smooth muscle contraction is evoked by a network of signals involving ion channels or membrane receptors such as the voltage-operated Ca 2+ channels or agonist-activated G-protein coupled receptors (GPCR) (Somlyo & Somlyo, 2003) . Depolarization of the smooth muscle cell membrane activates L-type Ca 2+ channels, resulting in calcium influx (Hermsmeyer et al., 1988; Moosmang et al., 2003) . The elevated intracellular calcium ([Ca 2+ ] i ) in turn activates Ca 2+ /calmodulin-dependent myosin light chain kinase (MLCK) which phosphorylates myosin light chain (RLC) to initiate myosin crossbridge movement on actin filaments (Kamm & Stull, 1985; Ito et al., 2004; He et al., 2008) . Agonists of GPCRs also sequentially activate Gα q/11 and phospholipase C, resulting in an increase in [Ca 2+ ] i by inositol 1,4,5-trisphosphate (IP 3 )-induced Ca 2+ release from the sarcoplasmic reticulum (Garay, 2000; Wynne et al., 2009) . After an initial elevation, [Ca 2+ ] i may subsequently decline, thereby reducing the extent of MLCK activation. However, other signaling modules are recruited to reduce the rate of RLC dephosphorylation by myosin light chain phosphatase (MLCP) (Somlyo & Somlyo, 2003; Hartshorne et al., 2004; Dimopoulos et al., 2007; Kitazawa, 2010; Grassie et al., 2011) . CPI-17, a specific inhibitor protein for MLCP, is phosphorylated by sequential activation of Gα q/11 and protein kinase C (PKC), leading to inhibition of MLCP activity (Eto et al., 2004; Butler et al., 2013) . Rho-associated protein kinase (ROCK) is also activated by Gα 12/13 activation induced by agonists, which then inhibits MLCP activity through MYPT1 and CPI-17 phosphorylation (Somlyo & Somlyo, 2000 . Therefore, the signals converging on MYPT1 and CPI-17 for MLCP inhibition are central to enhancing RLC phosphorylation and force maintenance while [Ca 2+ ] i decreases (Ca 2+ -sensitization) (Kitazawa et al., 2000; Kitazawa et al., 2003; Dimopoulos et al., 2007; Mori et al., 2011) .
The MLCP holoenzyme is composed of three distinct subunits: a catalytic type 1 phosphatase subunit (PP1cδ), a regulatory subunit (MYPT1), and a 20 kDa subunit of unknown function (Alessi et al., 1992; Shirazi et al., 1994) . MLCP dephosphorylation of RLC is involved in various biological processes involving different myosin II isoforms, including smooth muscle contraction, cell division, cell migration, morphogenesis and other developmental processes (Kawano et al., 1999; Xia et al., 2005; Yokoyama et al., 2005; Huang et al., 2008; Gutzman & Sive, 2010) . Biochemical observations show that PP1cδ activity is increased by binding to MYPT1, and inhibited upon MYPT1 phosphorylation (Trinkle-Mulcahy et al., 1995; Tanaka et al., 1998; Terrak et al., 2004) . MYPT1 also binds myosin and/or other proteins, thus serving as a scaffolding protein (Tanaka et al., 1998; Terrak et al., 2004) . MYPT1 may be phosphorylated by different kinases at multiple sites, including S432, S445, S472, S473, S601, S668, S692, S695, S852, S910, T696, and T853 (numbering based on human MYPT1) (Feng et al., 1999; Totsukawa et al., 1999; Wooldridge et al., 2004; Yamashiro et al., 2008; Zagorska et al., 2010; Yuen et al., 2011; Butler et al., 2013) . Among these, S668, S692, S695, S852 are phosphorylated by protein kinase G or protein kinase A with S695 and S852 inhibiting phosphorylation of T696 and T853 in smooth muscles (Wooldridge et al., 2004; Nakamura et al., 2007) . T696 and T853 can be phosphorylated biochemically by ROCK, ZIPK and ILK (Kimura et al., 1996; Feng et al., 1999; MacDonald et al., 2001; Muranyi et al., 2002) . Phosphorylation of T696 or T853 inhibits MLCP activity towards phosphorylated RLC in vitro (Trinkle-Mulcahy et al., 1995; Ichikawa et al., 1996; Muranyi et al., 2005; Khromov et al., 2009) . However, the role of MYPT1 phosphorylation at these sites in isolated tissues containing intact smooth muscle cells has been deduced primarily by pharmacological approaches with inhibitors of the multifunctional kinase ROCK.
These data indicate that unidentified protein kinases (not PKC) phosphorylate T696 while ROCK is primarily responsible for the phosphorylation of T853. Investigations of these signaling pathways need additional approaches to rule out off target effects where pharmacological inhibitors may act non-selectively on other protein kinases that affect contractile responses in different signaling modules. Additionally, inhibition of ROCK would result in inhibition of other proteins phosphorylation that affects contractile responses in addition to inhibition of T853 phosphorylation. Because ROCK is considered as a potential therapeutic target related to its ability to inhibit force maintenance in different smooth muscle tissues (Fernandes et al., 2007; Fonseca et al., 2009; Satoh et al., 2011; Zhou et al., 2011; Fukumoto & Shimokawa, 2013; Vesterinen et al., 2013) , it is important to understand its mechanistic importance relative to MYPT1 T853 phosphorylation.
Previous investigations show ileal and urinary bladder smooth muscles contract and relax in MYPT1-depleted tissues although RLC phosphorylation and force maintenance may be enhanced (He et al., 2013; Tsai et al., 2014) . However, these studies did not address specifically the role of MYPT1 T696 and T853 phosphorylation. To test the hypothesis that MYPT1 regulates force maintenance through phosphorylation at these two sites in vivo, we mutated MYPT1 individually in mice with alanine substitution at T694 and T852
(corresponding to human T696 and T853 respectively) to inhibit phosphorylation. Analyses of contractile and biochemical responses of isolated urinary bladder smooth muscle from mice containing the T694A mutation suggest that phosphorylation of MYPT1 T694 is required for force maintenance, and the underlying mechanism involves constitutive phosphorylation without dependency on ROCK activity. In contrast, results obtained with bladder smooth muscles from mice containing the MYPT1 T852A mutation suggest phosphorylation induced by G 12/13 /RhoA/ROCK has no significant effect on RLC phosphorylation and contractile responses. Based on these results, we proposed a novel model regulating force maintenance of urinary bladder smooth muscle.
Methods

Ethical approval and bladder isolation
All experiments were conducted in accordance with Animal Care and Use Committee of Model Animal Research Center of Nanjing University. Pregnant mice were sacrificed by cervical dislocation, and the pups at E18.5 were collected by caesarian section. The pups were immersed in ice to induce hypothermia. Once deep hypothermia was achieved, animals were decapitated, the bladders removed and transferred to cold HEPES-Tyrode (H-T) buffer (137 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl 2 , 1.8 mM CaCl 2 , 10 mM HEPES, and 5.6 mM glucose, pH 7.4) for force measurement and protein preparation. The bladders isolated from P0 pups were prepared similar to that from E18.5 pups.
Generation of Mypt1 mutant mice
The Mypt1 targeting vector was constructed by use of BAC (bacterial artificial chromosome)-retrieval methods (Liu et al., 2003) . 
Genotyping by Southern blotting and PCR analyses
Genomic DNA of ES cells were extracted and screened for positive clones by long distance 
Measurement of smooth muscle contractility
Smooth muscle strips (1 mm wide and 2.8-3 mm long dissected from the mid-portion of the urinary bladder in the circular direction) (Ekman et al., 2005) were tied to one end of a steel rod with the other end tied to a force transducer (MLT0201; ADInstruments) and placed in an organ bath (5 ml) at 37°C. The strips were stretched to 0. 
Protein sample preparation and Western blots
For measurements of contractile and regulatory protein expression, whole bladder tissues were homogenized in a sample buffer solution (2% SDS, 10 mM dithiothreitol (DTT), 10%
glycerol, a trace amount of bromophenol blue and 50 mM Tris HCl, pH 7.4), heated at 85°C
for 5 min, and incubated at room temperature for 60 min. After centrifugation at 10,600 g for 10 min, the supernatant fraction was subjected to SDS-PAGE and either stained with To measure MYPT1, CPI-17 and RLC phosphorylation, tissue strips were rapidly frozen by immersion in a frozen slush of 10% trichloroacetic acid (TCA) and 10 mM DTT in acetone pre-cooled by liquid nitrogen. The strips were then slowly thawed at room temperature followed by a thorough homogenization in 10% TCA and 10 mM DTT. The samples were centrifuged and the pelleted protein washed with diethylether. The protein samples were dissolved completely in an 8 M urea solution (He et al., 2008; He et al., 2013) .
Equal amounts of protein were mixed with Laemmli buffer (2% SDS, 10% glycerol, 0.002% bromophenol blue, 0.125 M Tris HCl, pH6.8), and boiled for SDS-PAGE with one of three polyacrylamide gradients (6%, 7.5%, or 12%). The resolved proteins were blotted to PVDF membranes. The membranes were blocked with 5% non-fat milk and then incubated individually with primary antibodies at 4°C overnight. The corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies were added after washing. The primary antibodies include a Phospho-MYPT1-T694 antibody, a Phospho-MYPT1-T852 antibody
(1:1000, MBL, Inc), a MYPT1 antibody (1:2,000, Upstate Biotechnology, Lake Placid, NY, USA), a Phospho-RLC-S19 antibody (1:1000, Cell Signaling Technology), a RLC antibody
(1:1000 Cell Signaling Technology), a Phospho-CPI-17 antibody (1:5000 Bio-World) and a CPI-17 antibody. The blots were visualized by using the enhanced chemiluminescence (ECL) method (PIERCE) and quantified using a Jieda 801 Image Analysis System 3.3.2 (JEDA Science-Technology Development Co., Ltd., Nanjing, China).
Myosin RLC phosphorylation was also measured alternatively by urea/glycerol-PAGE as previously described (He et al., 2008; He et al., 2013) . Briefly, protein was prepared from the tissue samples by using TCA precipitation as described above and after dissolving in urea sample buffer, subjected to PAGE in glycerol and then transferred to a PVDF membrane. The RLC protein was visualized following Western blotting with RLC antibody. The percentage of phosphorylated RLC relative to the total RLC protein level was quantified using a Jieda 801 Image Analysis System 3.3.2 (JEDA Science-Technology Development Co., Ltd., Nanjing, China).
Histology
Bladder tissues were fixed by 4% paraformaldehyde overnight at 4°C, dehydrated with a graded series of ethanol solutions, and embedded in paraffin. The embedded tissues were transversely sectioned at a thickness of 6 μm and slides were dewaxed with xylene, rehydrated with descending grades of ethanol, and then rinsed with distilled water. Tissue sections were then stained with hematoxylin and eosin to examine the morphology and the smooth muscle areas of the cross-sections were calculated from light microscopy images (Dotslide, Olympus).
Reverse transcription-PCR
Total RNA from bladders or other tissues was extracted using TRIzol (Invitrogen). 500 ng of RNA from each sample were used for reverse transcription and amplification. Primer (5'-TCC ACC ACC ACC CTG ACT ACA AC -3') and primer (5'-CTT GTT CTC TGG TTC TCG TAG AAC -3') were used for amplification of Mypt1 mRNA containing 694 site. Primer (5'-TCG TCC TCA CTC TCT ACT CTA GG -3') and primer (5'-AAC TGT ATG AAG CAG AGC GAC CC -3') are for Mypt1 mRNA containing 852 site. Primer (5'-ATT CCT TGC TGG GTC GCT CTG C -3') and primer (5'-ATC AAG GCT CCA TTT TCA TCC -3') are for splice variants of Mypt1 exon 23 (E23) (Fu et al., 2012) and PCR products were separated by 2% agarose gel electrophoresis.
Statistical analyses
Data are presented as the mean ± SEM with the number of observations shown in parenthesis.
The statistical significance of the differences between groups was determined by using Student's t-test.
Results
MYPT1 T694 and T852 phosphorylation in bladder smooth muscle
Since the phosphorylation patterns of MYPT1 are dependent on the kind of smooth muscle as well as animal species (Dimopoulos et al., 2007; Neppl et al., 2009; Maki et al., 2010; Hudson et al., 2012) , we first examined the MYPT1 T694 and T852 phosphorylation responses to KCl and the muscarinic receptor agonist bethanechol in isolated bladder tissues.
We detected only a weak phosphorylation of T852 under resting conditions. However, the extent of T852 phosphorylation was increased rapidly after treating with KCl, bethanechol or carbachol ( Fig. 1A , B, F and J). To identify the signaling module responsible to T852 phosphorylation, we tested the effect of kinase inhibitors. The increase in T852 phosphorylation was inhibited 60%-80% by the ROCK inhibitor Y27632, and less (KCl, 10-40%; CCh, 10-50%) by PKC inhibitor GF-109203 (Fig. 1D, F, H and J) . This result indicates that the induced phosphorylation of T852 is predominantly catalyzed by ROCK. In contrast, we detected a strong signal for T694 phosphorylation under resting conditions, and this phosphorylation did not increase significantly after treatment with KCl or bethanechol or carbachol ( Fig. 1 A, B, E and I) . Addition of calyculin A, a potent PP1 and PP2A phosphatase inhibitor capable of preventing MYPT1 dephosphorylation (Hirano et al., 1992; Kiss et al., 2008; Cho et al., 2011; Gao et al., 2013) , did not increase the extent of T694 phosphorylation, while it led to a marked and significant increase in T852 phosphorylation (Fig. 1C ). We also examined the effect of ROCK and PKC inhibitors on T694 phosphorylation. Neither Y27632
nor GF-109203 affected T694 phosphorylation ( Fig. 1D , E, H and I). These results indicate that T694 was highly phosphorylated constitutively and the lack of an increase with calyculin A suggests it may be 100% phosphorylated in bladders from E18.5 tissue (Tsai et al., 2014) .
We also test T694 phosphorylation of postnatal tissue (P0) and found a similar result. On the other hand, T852 phosphorylation was inducible by both KCl and cholinergic agonists and increased greatly with calyculin A treatment.
In addition to RLC, CPI-17 phosphorylation was also increased with both KCl and bethanechol treatments ( Fig. 1 A and B) and inhibited with the PKC inhibitor, but not the ROCK inhibitor (Fig. 1 D , G, H and K) .
Generation and characterization of MYPT1 T694A and MYPT1 T852A mutant mice
To assess the role of T694 and T852 phosphorylation in smooth muscle contraction in vivo,
we established two lines of knockin mice with replacement of T694 or T852 with alanine, in which ACA codon of a threonine at 694 or 852 of MYPT1 was mutated to GCA encoding alanine. We introduced these mutations into the mouse genome through a standard homologous recombination method including ES electroporation, microinjection to blastocysts with the right targeted ES cell clones (Fig. 2B ) and establishment of chimeric founders. The detailed scheme is represented in Fig. 2A . To obtain a germ line of T694A mutant, we crossed male chimeric mice of T694A with C57BL/6 mice. Unfortunately, we failed to obtain a Mypt1 T694A/+ heterozygote among 232 pups. We injected alternative ES clone for generating chimeric mice, but we still could not obtain a Mypt1 T694A/+ heterozygote.
Thus, loss of the heterozygotes was unlikely caused by abnormal ES clones, because karyotyping analysis showed normal chromosomes of the MEF cells from Mypt1 T694A/+ heterozygotes (data not shown). We then examined the embryos at embryonic day 18.5 (E18.5) and found that T694A mutant embryos appeared in an expected Mendelian ratio. One hundred percent of these mutants had severe omphalocele, whereas body sizes and survival appeared normal (Fig. 2C) . Loss of Mypt1 T694A/+ heterozygote after birth was due to cannibalization by mother mice. We confirmed the mutation with multiple analyses (Fig.   2D-F (Fig. 2D, G and H) .
Using a similar strategy, we introduced T852A mutation of MYPT1 into mice with germ line transmission ( Fig. 2A) . The mutation of the resultant heterozygous (Mypt1 3A and B and Fig. 4A and B) . Additionally, the thickness of the smooth muscle layer was not altered (Fig. 3D and 4D ). Histological examination showed normal mucosa, submucosa and smooth muscle layers in the bladder walls among all lines. Typical histology was represented in Fig. 3C and Fig. 4C . Therefore, we concluded that mutation of T694A or T852A did not affect bladder development.
To assess compensatory expressions of contraction-related proteins after mutation, we measured smooth muscle myosin heavy chain (SM-MHC), MLCK, PKC, PP1cδ, RLC, CPI-17, α-smooth muscle Actin (α-SMA), myosin phosphatase-rho interacting protein (M-RIP) and prostate apoptosis response-4 (Par-4) proteins in mutant bladder smooth muscles, and found no apparent alteration of these proteins among Mypt1
Mypt1
T694A/+ mice ( Fig. 5A-C) . Similar results were obtained in the T852A mutant smooth muscle ( Fig. 5D-F) .
Reduced force responses of isolated tissue from MYPT1 T694A mutant mice
Since we could not obtain adult smooth muscle tissues from T694A mutant mice, we analyzed contractile responses of the bladder smooth muscle from E18.5 mice. We mated Fig. 6C and F) . To further confirm the effect of T694A mutation on force maintenance, we measured force responses at 5 minutes after different doses of carbachol. The force responses were normalized to the maximal forces induced by 100 μM carbachol. As shown in Fig. 6G , there was a reduction of force associated with the MYPT1 T694A mutation at different concentrations of carbachol.
Taken together, our results showed that the MYPT1 T694A mutation led to reduction of force maintenance in bladder smooth muscle.
Reduced RLC phosphorylation of MYPT1 T694A mutant muscle in the late phase of contraction
In vitro studies indicate phosphorylation of MYPT1 at T694 inhibits MLCP dephosphorylation of phosphorylated RLC (Feng et al., 1999; Muranyi et al., 2005; Khromov et al., 2009 and then declined more rapidly (16 ± 2% vs 9 ± 2% at 180s) ( Fig. 7A and B) . Similar results were obtained by comparing RLC phosphorylation responses in bladder smooth muscles from Mypt1 T694A/+ and Mypt1 +/+ mice (60s: 5 ± 0.5% vs 13 ± 2%; 180s: 3 ± 1% vs 8 ± 2%, Fig. 7 C and D) . To test if the reduced force of T694A muscle was caused by the reduced RLC phosphorylation, we applied calyculin A, an inhibitor of PP1 and PP2A phosphatases (Ishihara et al., 1989; Henson et al., 2003) . After incubation with calyculin A, control bladder smooth muscle generated a force response that was 43.7 ± 4% of the maximal force induced by KCl (Fig. 7E and F 
Mypt1
+/+ mice treated with KCl, showed that the former tissues had less force than the latter tissues at various times although the differences were modest (Fig. 8E ), e.g. five minutes after KCl treatment, the sustained force had declined to 10.2 ± 1.0% of maximal force in muscles from Mypt1 T852A/T852A mice, which was significantly lower than the value (14.1 ± 0.9%; p < 0.01) from Mypt1 +/+ control mice (Fig. 8E) . Similar results were obtained from
T852A/T852A mice of P0 (Fig. 8H ). Upon stimulation with carbachol (E18.5) or bethanechol (P0), the average sustained force of Mypt1 T852A/T852A bladder smooth muscle was less than that of Mypt1 +/+ control, but no statistical significance was observed (all p > 0.05) ( Fig. 8F and I) . Thus, the MYPT1 T852A mutation had modest effects on the sustained contraction of embryonic bladder smooth muscles.
Since MYPT1 T852 phosphorylation inhibits MLCP activity in vitro, we measured RLC phosphorylation during contraction. Consistent with results obtained on contractile force responses, RLC phosphorylation of Mypt1 T852A/-bladder smooth muscle was comparable to that of Mypt1 +/-(all p > 0.05 at 15 seconds, 1 minute and 3 minute after stimulation) (Fig. 8J ).
This indicates that MYPT1 T852 phosphorylation does not apparently influence MLCP activity towards RLC dephosphorylation in vivo.
Contractile response to ROCK inhibitor in MYPT1 mutant smooth muscle
MYPT1 phosphorylation is reported to be associated with calcium sensitization through ROCK signaling pathways (Somlyo & Somlyo, 2003; Wang et al., 2009; Kitazawa, 2010; Hudson et al., 2012) . To test whether MYPT1 T694 and T852 phosphorylation is functionally dependent on ROCK signaling, we measured the contractile responses of mutant bladder smooth muscles with ROCK inhibition. In smooth muscles from control mice and mice containing MYPT1 T694A mutations, pre-addition of 10 μM Y27632 did not inhibit the maximal contractile responses to KCl (all p > 0.05) ( Fig. 9A and B) . However, sustained contractile responses were significantly inhibited in tissues from control mice (Mypt1 . Similarly, we also examined the effect of ROCK inhibitor H1152 on CCh-evoked contractile response. The sustained tension of Mypt1 T694A/-smooth muscle was significantly inhibited in the presence of 0.1 μM H1152 (p < 0.05), in a similar manner of Mypt1 +/-control ( Fig. 9D-F) . These results indicate that force maintenance by T694 phosphorylation was independent of ROCK signaling, consistent with MYPT1 T694 phosphorylation measurements ( Fig. 1E and I) .
We also measured the effects of ROCK inhibitor on smooth muscle responses with tissues from mice containing the MYPT1 T852A mutation. Similar to T694A mutation, the bladder smooth muscle isolated from Mypt1 T852A/-, Mypt1 T852A/T852A , Mypt1 +/-and Mypt1 +/+ mice were sensitive to ROCK inhibitor in sustained, but not maximal force responses (Fig. 10A-C) . A more selective inhibitor of ROCK, H1152, also showed similar effect ( Fig. 10D-I ). These results suggest that T852 phosphorylation is not necessary for the force inhibitory effects of the ROCK inhibitor. To investigate why inhibition of ROCK was able to relax these mutant smooth muscles, we examined the effect of ROCK inhibition on LIMK/cofilin/F-actin cascade. Upon pretreatment with vehicle, KCl modestly induced cofilin phosphorylation within 20 seconds and 5 minutes in Mypt1 +/+ bladder smooth muscle. Upon pretreatment with 10 μM Y27632, the cofilin phosphorylation was significantly inhibited at 5 minutes (p < 0.05) ( Fig. 11A and B) . Interestingly, in Mypt1 T694A/-and control muscle, treatment with Y27632 also significantly inhibited cofilin phosphorylation at 5 minutes (Fig. 11C) . Thus, the inactivation of cofilin by phosphorylation may contribute to force development by enhanced actin dynamics. The inhibition of ROCK appears to inhibit cofilin phosphorylation and thus inhibits force development.
Discussion
As the main regulatory subunit of MLCP, MYPT1 appears to regulate the phosphatase activity biochemically through multiple mechanisms (e.g. serving as a binding subunit, In response to physiological and pharmacological stimuli, smooth muscles initially develop a rapid maximal force response through activation of Ca 2+ /calmodulin-dependent MLCK (Kamm & Stull, 1985 He et al., 2008; Zhang et al., 2010; He et al., 2011) T694 phosphorylation was not inhibited by ROCK or PKC inhibitors, similar to other reports for bladder smooth muscle (Wang et al., 2009; Wang et al., 2012) . Additionally, treatment of bladder tissues with calyculin A did not further increase MYPT1 T694 phosphorylation.
Because calyculin A treatment results in 100% phosphorylation of MYPT1 T694 (as well as T852) in adult bladder smooth muscle (Tsai et al., 2014) , MYPT1 T694 may be similarly phosphorylated in embryonic bladder smooth muscle.
Pharmacological perturbations affecting MYPT1 T852 and CPI-17 phosphorylation associated with diminution of force responses have formed a fundamental model of signaling mechanisms for the force maintenance in a variety of smooth muscles (Kitazawa et al., 2003; Niiro et al., 2003; Dimopoulos et al., 2007; Wang et al., 2009) . However, using a genetic approach to knockin nonphosphorylatable alanine for T852 or T694, we found that MYPT1 T852A mutation had no significant effect on maximal force development and little effect on force maintenance in isolated bladder tissues. Information about MYPT1 T852 phosphorylation as well as its functional roles are conflicting (Feng et al., 1999; Muranyi et al., 2005; Khromov et al., 2009; Khasnis et al., 2014) . For example, Feng et al. (1999) suggested that T852 is not an inhibitory site for MLCP activity; Khromov et al. (2009) demonstrated in vitro that T852 phosphorylation displayed 30-fold less activity than T694;
Hartshorne et al. concluded that T852 phosphorylation regulated MLCP activity equivalently to T694 (Muranyi et al., 2005) . Several reports propose that the regulatory mechanism of T852 is direct inhibition of PP1c activity through T852 phosphorylation (Feng et al., 1999; Khromov et al., 2009) Neurostimulation resulted in increased phosphorylation of CPI-17, but not MYPT1, in gastric fundus or urinary bladder smooth muscles (Tsai et al., 2012; Bhetwal et al., 2013) . However, pharmacological stimulation of muscarinic receptors increased MYPT1 as well as CPI-17 phosphorylation in both types of smooth muscles. The inducible increase of T852 phosphorylation observed in these two smooth muscle tissues may be due to pharmacologically intense activation of signaling modules not observed physiologically. In contrast, the myogenic response in arterial resistance vessels was associated with MYPT1 T852 phosphorylation and increased actin polymerization, but no CPI-17 phosphorylation (Moreno-Dominguez et al., 2013) . These responses were all diminished with ROCK inhibition implicating ROCK-dependent contribution to the myogenic response by MYPT1
T852 and/or cofilin phosphorylation. Recent studies confirmed the importance of ROCK in cofilin phosphorylation and enhanced actin polymerization in the myogenic response (Moreno-Dominguez et al., 2014) .
We also found that most of MYPT1 T694 was phosphorylated constitutively, and was not reduced by ROCK or PKC inhibitors that did affect MYPT1 T852 or CPI-17 phosphorylation.
Such a constitutive phosphorylation is obviously not catalyzed by ROCK1/2 and PKC.
Whether it is catalyzed by zipper interacting protein kinase (ZIPK), integrin-linked kinase (ILK), or p21-activated kinase remains unknown (MacDonald et al., 2001; Muranyi et al., 2002; Takizawa et al., 2002) . Our previous observations from the selective knockout of MYPT1 in smooth muscle tissue (He et al., 2013; Qiao et al., 2014; Tsai et al., 2014) suggest existence of a constitutive Ca 2+ sensitization under resting conditions. Biochemical analysis
shows that the reduced PP1cδ activity in MYPT1-deficient tissues appears similar to the attenuated MLCP activity in wild type tissues resulting from the constitutive phosphorylation of MYPT1 T694 (Tsai et al., 2014) . In this report, we showed that the MYPT1 T694A mutation significantly inhibited sustained force as well as RLC phosphorylation. Thus, we suggest that smooth muscles have a constitutive Ca 2+ sensitization mechanism contributing to force maintenance via MYPT1 T694 phosphorylation. In contrast to constitutive phosphorylation, pharmacological agonist-induced Ca 2+ sensitization may be primarily contributed by the CPI-17 phosphorylation response (Kitazawa et al., 2000; Sakai et al., 2007; Kitazawa, 2010) and other protein phosphorylations by ROCK.
There are some caveats in considering these results on functional effects related to MYPT1
T694A or T852A mutations. Due to development of omphalocele, results were limited to E18.5 or P0 tissues. There might be some minor distinctions in contractile performance between E18.5/newborn and adult tissues (Ekman et al., 2005) . We thus are cautious in interpretations relative to adult tissues, Secondly, these results are focused on bladder smooth muscle and additional investigations are needed to extend observations to other kinds of phasic smooth muscles in addition to tonic smooth muscles.
In conclusion, constitutive phosphorylation of MYPT1 at T694 appears to mediate sensitized force maintenance through inhibition of MLCP activity, whereas agonist-induced T852 phosphorylation has no apparent role in regulating contractile responses. Our observations provide novel mechanistic insights into the specific role of MYPT1 phosphorylation on physiological and pharmacological Ca 2+ sensitization.
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F Figure 11. Depolarization induced cofilin phosphorylation was attenuated by ROCK inhibitor Y-27632
A, bladder strips from P0 mice were preincubated for 15min with 10 μM Y27632 followed by 124 mM KCl containing Y27632 as indicated. Cofilin phosphorylation was analyzed by
Western blot assay, and total cofilin was used for loading control. The quantitation is shown in B and the data is analyzed with Student's paired t test. N=5, *p < 0.05 (compared with vehicle at the same time). C, Western blot analysis shows preincubation with Y27632
attenuates cofilin phosphorylation both in T694A mutant and control bladder strips at 5 minutes after 124 mM KCl stimulation.
